LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.

Studied

A full-text phase 1 program tested the dual GIP/GLP-1 agonist LY3298176 in cells and mice, then in randomized, double-blind human studies against placebo; dulaglutide was an active control in healthy participants. Safety and tolerability were primary.

Who / model

A total of 142 people received LY3298176, placebo or dulaglutide: 56 in the single-dose study, 33 healthy participants in the four-week multiple-dose study and 53 people with type 2 diabetes in the proof-of-concept study.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

After four weeks, higher-dose groups with diabetes had lower fasting glucose versus placebo, and several healthy-participant groups lost more weight versus placebo. Gastrointestinal events were dose-dependent and mild to moderate; vomiting limited the single 8 mg dose.

Limits

The trials were short and small, ethnic backgrounds differed between cohorts, dulaglutide was studied only in healthy participants, and the design could not separate GIP from GLP-1 contributions.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary